Good morning and welcome to Paratek's First Quarter 2021 Earnings and Corporate Update Conference Call. A press release with the company's first quarter results was issued earlier today and we have also posted slides in our website that will be referred to on this call.

Both can be found at www.paratekpharma.com. Participants on today's call are Evan Loh, CEO; Adam Woodrow, President and Chief Commercial Officer; Randy Brenner, Chief Development and Regulatory Officer; Michael Bigham, Executive Chairman; and Sarah Higgins, Vice President of Finance Controller and Principal Accounting Officer will also be available for questions.

Before I turn the call over to over to Evan, I would like to point out that we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially.

I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Evan?

Thank you, Ben. Good morning and thank you all for joining our first quarter earnings and corporate update call.

We believe 2021 will be a transformative year of continued growth for Paratek. NUZYRA's quarter-over-quarter growth in 2020 continued into the first quarter of this year.

We believe this is not only a significant achievement in this volatile and rapidly evolving healthcare setting, but also a reflection of the clinical importance of positive patient outcomes with NUZYRA in the hands of clinicians. Our first quarter 2021 results were consistent with our expectations as NUZYRA generated U.S.

net sales of $13.2 million in the first quarter, reflecting the health of our commercial business. Our confidence in the long term commercial success of NUZYRA remains unabated based upon growing demand of NUZYRA in the hospital care setting, coupled with the recent initial positive signs of new prescriptions and adaption in the primary care commercial expansion.

We anticipate that this growth trajectory will continue through the balance of 2021, given the encouraging initial inbound feedback from the primary care based physicians for a well-tolerated, once-daily, oral, broad spectrum antibiotic that includes coverage against MRSA for skin infections. As seen in this next slide, the commercial success to-date has established NUZYRA as one of the most successful antibiotics launched in the last five years.

NUZYRA continues to materially differentiate itself from other IV oral antibiotic launches driven by strong operational execution and NUZYRA's many product attributes that include: first, broad spectrum efficacy including resistant pathogens across two common indications; second, a favorable safety profile consistent with NUZYRA's tetracycline heritage; and third, convenient once-daily, oral and IV formulations that enable utility in multiple settings of care. In addition to the commercial business, we are focused on several exciting and potentially transformative catalysts for Paratek.

First, we're excited to announce that BARDA has initiated the first procurement of NUZYRA valued at approximately $38 million. We expect that this procurement will be delivered and recognized this quarter.

Second, an important FDA decision on the NUZYRA sNDA for the oral loading dose regimen in pneumonia. If approved, we believe this will be an important catalyst to further-expand the commercial opportunities for NUZYRA in the primary care setting.

Third, the initiation of a Phase 2b study for NUZYRA in a rare disease, pulmonary NTM abscesses, for which there are no approved therapies. Fourth, we anticipate the second part of procurement in the second half of this year.

Fifth, we anticipate in approval of NUZYRA in China, one of the largest potential antibiotic markets, which will trigger a $6 million approval milestone payment from ZyLAB to Paratek. And finally, in addition to these catalysts, we continue to actively evaluate potential assets to expand our portfolio and leverage our commercial infrastructure.

Before I hand the call to Adam, I would now like to provide Paratek's first quarter 2021 financial highlights. First quarter 2021 total revenue was $16.4 million, an increase in 3% over the prior quarter, and 107% over the first quarter of 2020.

NUZYRA generated $13.2 million in net U.S. sales in the first quarter, an increase of 6% over the prior quarter and an increase of 81% over the first quarter of 2020.

First quarter 2021 government contracts service and grant revenue earned under the BARDA contract, were $2.6 million for the first quarter versus $2.8 million in the fourth quarter of 2020. We anticipate a modest step up in contracts service and grant revenue earned under the BARDA contract as we move through the year, driven by activities associated with the on-shoring in the U.S.

of NUZYRA at manufacturing that continue in enrollment of the FDA post-marketing required studying pneumonia, and further advancement of the preclinical work in the anthrax program. First quarter R&D expenses were $5.5 million, compared to $6.4 million for the same period in the prior year.

Included in R&D expenses for the first quarter were $2.7 million in costs reimbursed under the BARDA contract for the U.S. on-shoring of NUZYRA manufacturing and for FDA post-marketing requirements.

The decrease in R&D expense is primarily a result of lower third party manufacturing process scale up and clinical study costs, as well as lower stock-based compensation expense partially offset by an increase in the reimbursable costs incurred under the BARDA contract. SG&A expenses were $22.4 million for the first quarter of 2021, compared to $23.6 million for the same period in the prior year.

The decrease in SG&A expense is primarily the result of a continued focus on driving operational efficiencies across the organization, as well as lower stock-based compensation expense. As of March 31, 2021, we had $103.5 million in cash and cash equivalents.

Based upon our current operating plan, we anticipate our existing cash and cash equivalents provides for a cash runway through the end of 2023 with a pathway to cash flow breakeven. I would now like to turn the call over to Adam.

Adam?

Thanks, Evan. The commercialization of NUZYRA continue to progress well with consistent quarter-over-quarter growth since its launch, even in the face of the ongoing COVID-19 pandemic.

As you can see from Slide 11, NUZYRA net revenue grew 6% in the first quarter when compared to the fourth quarter of last year. NUZYRA gross demand increased from approximately $13.5 million in the fourth quarter of 2020 to approximately $14.6 million in the first quarter of 2021 and thus the growth in the first quarter was driven by demand.

In the first quarter, our sales were impacted by the typical New Year insurance resets, in addition to recruiting and training and new salesforce and the ongoing challenges presented by COVID-19 that we have discussed in the past. Nevertheless, our business grew quarter-over-quarter as we effectively and efficiently operated within our hybrid sales model that consisted of both face-to-face and virtual interactions.

We see COVID and the related access challenges occurring well into the second half of 2021, but with a steady shift to the more impactful face-to-face interactions as the year progresses. NUZYRA's once-daily, well-tolerated oral and intravenous formulations combined with NUZYRA's broad spectrum profile offers a much needed new life-saving antibiotic that is uniquely positioned to be applicable in every setting of care.

From the hospital and it's potential to minimize hospital stays, to the community where there is a tremendous unmet need for a well-tolerated once-daily oral broad spectrum antibiotic that includes coverage against MRSA for skin infections. Current generic antibiotic options in the community are challenged by either significant bacterial resistance or serious safety concerns, limiting their utility.

This is verified by our utilization data from our primary care pilot and the initial results from our primary care expansion seen so far this year. The data suggests primary care physicians' first trial of news NUZYRA occurs quicker and with fewer calls than the hospital based physicians.

This dynamic is playing out as we have seen encouraging signs in prescription numbers driven from our primary care expansion efforts. We anticipate this momentum will continue through 2021 as we maintain our focus on gaining institutional access, continuing to support the primary care expansion, building awareness and trust and credibility with physicians who are saving lives and treating serious community-acquired infections every day.

Our sales team is now near our targeted headcount, following significant recruitment efforts that occurred in the first quarter. We now have approximately 80 representatives with half focused on the hospital and half focused on primary care.

As described last quarter, our initial launch into primary care will focus on the estimated $2.2 billion addressable market opportunity for skin infections, which represents the largest targeted segment for NUZYRA promotion. Later this year, after the anticipated approval of the pneumonia, oral only loading dose regimen, we plan to expand our promotion to include pneumonia in the community, which represents an additional estimated $1.5 billion addressable market opportunity.

A recent study published by Pew [ph] also reports and reinforces the potential role NUZYRA can play in addressing unmet needs for community-acquired infections. The study highlighted the potential risks of toxicity and adverse events associated with fluoroquinolones use with the panel recommending the alternative and equally effective antibiotic agents should always be favored over fluoroquinolones when available.

In this study, 47% of all fluoroquinolone, and 27% of all Vancomycin prescriptions were deemed inappropriate. As a result, the panel recommended a national target to reduce inappropriate use for each of these antibiotics by some 95%.

This data reinforced the unmet clinical needs and suggest that NUZYRA could provide an important clinical alternative in some circumstances. We believe we're on the right path with NUZYRA and are well-positioned for long term commercial success.

We look forward to reporting on our continued progress in the quarters ahead. And with that, I'd now like to turn the call over to Randy.

Thanks. Thanks, Adam.

As you heard from Evan a few minutes ago, we are excited to announce that BARDA has initiated the first procurement of NUZYRA valued at approximately $38 million that we expect will be delivered this quarter. We also continue to advance the preclinical, clinical and manufacturing work under the BARDA contract.

In addition to BARDA activities, we are progressing our pipeline with the startup activities for our Phase 2b study in the rare disease pulmonary NTM abscesses with study initiation expected next month and the recent initiation of the pneumonia post-marketing study required by FDA. We continue to actively pursue lifecycle initiatives for NUZYRA.

Later this month, we are anticipating a decision from the FDA on our sNDA for our oral loading dose regimen for community acquired bacterial pneumonia. We also continue to advance our clinical development program for our rare disease, non tuberculous mycobacteria pulmonary disease caused by mycobacteria abscesses, or NTM.

As a reminder, pulmonary NTM abscesses is an orphan disease with no FDA-approved therapies. Inbound feedback from the KOL community has continued to highlight the clinical unmet need for an efficacious and well-tolerated once-daily oral antibiotic to treat infections caused by Mycobacterium abscesses.

Based upon our internal market analytics, pulmonary Mycobacterium obsesses represents an estimated $1 billion addressable market in the U.S. alone.

We are in advanced in the startup activities for our Phase 2b study for this disease with the initiation of the study planned in June. We will provide more details about the safety and efficacy endpoints, which includes symptom and microbiology assessments at an upcoming meeting to be announced in the near term.

NTM is an exciting lifecycle opportunity for NUZYRA with significant potential to address important unmet medical needs. Our BARDA partnership also continues to progress well.

This unique public private partnership is in recognition of our jointly shared commitment to advancing NUZYRA in the fight against antimicrobial resistance and to develop NUZYRA as a potential treatment against bio-terrorism pathogens, including anthrax and the procurement of NUZYRA for the Strategic National Stockpile. In addition to initiating the first procurement, we, along with BARDA continue to make important progress advancing our anthrax animal roll program, as well as our efforts to onshore manufacturing of NUZYRA that will enable us to secure additional supply chain for NUZYRA within the U.S.

To the best of our knowledge, NUZYRA will be the first and only antibiotic to be made exclusively in the U.S., including API production. With regards to the anthrax animal roll program, we have generated data in over 130 Bacillus anthracis isolates that continues to confirm the in vitro potency of news NUZYRA against this potentially life-threatening pathogen.

Importantly, this testing also included a strain resistant to ciprofloxacin and a separate strain resistant to doxycycline. Against both of these strains, Omadacycline remained active with its in vitro potency maintained.

In addition to that data, we originally received data for work we conducted with the United States Army Research Institute of Infectious Disease, also known as USAMARIID, testing Omadacycline in many panels against various resistance strains of Bacillus anthracis, including a multi-drug resistance strain resistant to all other antibiotic classes. Against this multi-drug resistant strain Omadacycline retained its activity and in vitro potency, suggesting NUZYRA could be the only viable option for multi-drug resistant strains of Bacillus anthracis.

This data support the potential utility of NUZYRA and pandemic preparedness against antibiotic resistant biothreats. In addition, a recent poster from Asper [ph] at the 2021 National Association of City and County Health Officials Preparedness Summit highlighted the challenges with secondary infections resulting from chemical, radiologic, nuclear and biologic threats.

We're looking closely at the infection types and/or pathogens highlighted in this poster. NUZYRA already has either the approved indication or pathogen in it's USPI [ph] as shown in green boxes, or the in vitro data for the pathogen as shown in blue boxes, further confirming that NUZYRA had the potential to address several of these key pathogens.

Also at this conference, the CDC presented a poster regarding the recommended treatments for plague. In this poster, Omadacycline was included on the list of our alternatives for pre or post exposure prophylaxis of plague, another bacterial pandemic threat.

As a result, we anticipated the CDC to update their guidelines on pneumonic plague to include Omadacycline this summer. We believe these two recent posters continue to highlight the potential utility of Omadacycline in a growing list of threats, and we believe has the potential to open further opportunities with U.S.

government for future utilization and procurements. The scientific story will continue to expand throughout 2021 with the continued advancement of our IRR program.

The medical affairs team has several activities planned further support the community launch and the expansion of the scientific education into this new healthcare base. This includes the placement of a small number of targeted community based education specialists to further augment the primary care launch.

With regards to the NDA review in China, the regulatory process continues to make good progress, with the approval expected later this year, triggering a $6 million milestone payment from ZyLAB to Paratek. We believe that the China approval and the additional data generation opportunities will further broaden the potential for news NUZYRA to reach into new and clinically important patient populations.

At this point, we'd like to open the line for questions.

Congratulations on a number of levels. It's been it's been quite an effort and terrific, terrific results.

Just three brief ones. Could you give us some timetable for the enrollment of the 2b study in NTM?

Then secondly, your confidence with regard to further government, military or other procurement, just love some additional thoughts there. And then last but not least, as you contemplate further portfolio product expansion as you've mentioned, is that primarily with Omadacycline, or are we thinking more broadly?

Thanks and congratulations on all the progress once again.

Hi, Bert. Thank you very much for the questions.

I'll have Randy address the first question around timeline.

Yes. Thanks, Evan.

Hey, Bert. So, we will be providing a much more detailed update on our NTM study in an upcoming meeting that we'll be announcing soon.

We've said that based on the size of the study and the numbers of patients in this population, we expect about a two-year enrollment process for that study.

Okay, and then the...

Terrific. And then the potential for additional government procurement and your enthusiasm there and then potential expansion of either with or without Omadacycline?

Yes. We are extremely excited about the procurement being initiated here.

We do think that that is tremendously validating to the commitment within our public private partnership. In addition to that, as a reminder, NUZYRA last year was added to the joint deployment formulary, which I think opens up the possibility for future procurements broader throughout the Department of Defense.

Maybe I could have Adam comment on some of the efforts that his team has been exploring.

Thank you, Evan. Yes, hi, Bert.

Look, we continue to engage with a number of departments within the government about future stockpiling opportunities, especially with the recent stimulus package. NUZYRA could be an ideal choice for a new therapeutic option to add to the Strategic National Stockpile and we'll continue to explore other buyer threats and departments such as the Department of Defense and Military.

It's too early to predict how successful we'll be with these efforts. But rest assured we'll try hard.

And Burt, I'll take your third question with regards to potential product expansion, with regards to Omadacycline or something else. Look, I think as you can imagine, we monitor our sector very closely.

And having now a commercial presence in both the hospital and the community setting, I think gives us, Bert, greater flexibility to consider opportunities to expand our pipeline. Our first commitment has always been to build around opportunities around our lead asset, NUZYRA.

You heard from Randy today about the expanding lifecycle opportunities which we're excited about, given our core competencies and our established infrastructure and expertise to ensure that our franchise product NUZYRA to be successful. Given our position of strength, though, we believe we can potentially bring in additional assets, we continue to look for these assets.

But as always, we'll remain disciplined in our approach and carefully monitor our cash runway.

Thank you. Congratulations again.

Thank you, Bert.

Hi. Thanks for taking the questions.

Maybe first, congratulations on getting the initial procurement, moving from BARDA. Can you remind us of any deliverables needed for that second procurement that you expect later this year?

Randy, you want to take that one?

Yes, sure. So, thanks, Kevin.

We're excited that we achieved the first procurement; certainly continue to exactly exemplify BARDA's commitment to advancing the program. We continue to plan for this second procurement in the second half of this year.

As we've continued to state, the future procurements are tied to ongoing progress of the program. There's no specific milestone assigned specifically to each of them.

So, we'll continue to have discussions with BARDA to provide more specifics in the future about the exact timing and that procurement the second half of the year.

Great. And then switching over to Omadacycline in cap, we kind of had a bit of an abnormal cap season this year with everything with COVID.

How are you guys thinking about the next cap season? Do you expect something closer to normal?

Or do you anticipate that's still going to feel a lot of this COVID disruption as we start heading into next winter?

As we look at the success of the vaccination program throughout the U.S., we're very excited about that with regards to our commitment as a company to provide resources for improving health across all populations. And what was interesting was that the public health measures that were instilled during the COVID pandemic, that included social distancing, rigorous hand washing, as well as masking, really drove the community-acquired pneumonia rates to I think a lower rate than has been seen in many decades.

That being said, I think that we're seeing that the vaccination programs have been successful. With the recent CDC guidances, we see an expansion of folks being able to interact on a more pre-pandemic mass-less interaction basis and I think we'll start to see trends in the fall for a more normal pneumonia season.

That being said, I think that another aspect of our expansion for the NUZYRA franchise that I think will play into this quite a bit, given the fact that because of COVID, I think hospitals have been [ph] places where most patients and most doctors are trying to be very cautious about referring patients who are ill there. And as such, I think there will be a more concentrated effort to keep people out of the hospital and keep them home in our stay home strategy with regards to the oral-only potential loading dose for pneumonia, I think will play very well into that dynamic come the fall.

And if there is continued growth in the community expansion, as we started to see with the community launch with skin infections, especially those with MRSA considerations, I do think there will be I think a growth and opportunity come the fall.

Great. Appreciate that.

Maybe last one. Can you talk about -- you mentioned stockpiling opportunities in the U.S.

or at least government opportunities in the U.S. beyond the initial contract with BARDA.

Do you see opportunities with international governments as well? Would you need to have approval of NUZYRA in those countries before you would have these discussions?

Or would you be able to have discussions with other governments before you have NUZYRA approved in those markets?

Yes, thanks for that. I'll have Randy address that one.

Sure. So yes, we are continuing to pay attention to what's going on around the world with regards to antibiotic incentives which includes some potential for stockpiling.

You've probably read some of the European countries are thinking about doing some of those activities now as well. A precursor to many of those dose [ph] require regulatory approval in those countries.

That being said, as we continue to expand our database, particularly on pandemic preparedness and bio threats, we will continue to share that data and look for ongoing opportunities to look to ways to provide opportunity for X U.S. countries to look for stockpiling opportunities for buyer threats and antibiotic resistance as well.

In point of fact, Kevin, just to build on what Randy said, if you look at the essential medicines listing of NUZYRA in the bioterrorism category, as well as this recent poster that Randy mentioned in his presentation, specifically around the CDC moving to add NUZYRA as a second line option for plague, you can see that not only are we having a franchised product profile for, I think more bread and butter skin and pneumonia infections, I do think that the pandemic preparedness portfolio of commitments by the U.S. government is something that I think will be very hard for others to ignore in terms of what we are doing internally from a DOD perspective on preparedness and the commitments of BARDA, et cetera.

And I think that it will lead to other opportunities that we can explore outside of the U.S. as appropriate.

Thank you.

Thank you, Kevin.

Hi. Thanks for taking my question.

So, the first one is about NTM Phase 2b trial. I'm sorry, I missed it earlier, but when do you expect to share the trial design?

And I have follow up questions.

So yes, we're planning a meeting in the near future to really review in more detail, the NTM study design. So, that's coming shortly and I think Ben will provide more information once we were able to share the date of that meeting.

Thank you.

That all being said, Suji, I think that there's opportunity here for us to really be relatively innovative in terms of that approach given the fact that there are no approved oral therapies for this disease, and we are looking forward to being able to share that more broadly in an upcoming meeting that we'll announce shortly.

Okay, thank you. My next questions are on the expansion of NUZYRA into the community setting for CABP [ph].

How many additional salesforce do you expect to add to support the indication in their primary care setting? And second question is when do you expect to see the full impact of the expansion of salesforce to the community on the sales?

Thank you.

Adam, do you want to take that one?

Yes, I'll take that. Thanks, Evan.

Well, first of all, I'll take those in reverse order, actually. We expect to see the real impact of the expansion in the latter half of this year.

This field [ph] force was obviously recruited in the first quarter, is just getting up to speed as we move into the second quarter and the full impact will be realized in the second half. But early signs are extremely encouraging and we're really pleased with what we've seen.

As regards to whether we need new on additional representatives to support the cap launch [ph], the answer is simply no. We don't need to expand beyond where we plan to be, which would be a sort of steady state having about 40-45 hospital based representatives and about 40 in the community.

And the reason for that simply is that many of the individuals that prescribe the skin also overlap significantly with those that prescribed the community-acquired pneumonia. And so you get a double-hit on those individuals that you're targeting.

You might shift your focus a little bit. Both of these diseases are a bit seasonal, as you can imagine.

There's more skin infections in the summer and more pneumonia in the winter. So, you might reverse your order of detailing.

And you may over-index on certain positions for one indication rather than the other at some point in time. As we've stated in the past, we're very careful with putting lots and lots of representatives on the ground until we're sure that we'll realize the benefit.

And if we feel that we can benefit from putting more in, we'll look at that as sometime in the future.

I think that the other component of the timing of how we've expanded the community, Suji, I think is an important one to consider, which is that we believe that it was important always to have a solid foundation in the hospital setting to establish, I think, the credibility of the product in the sickest patients with infectious disease individual and physicians being the primary prescriber. The other I think feature of the predicate for setting the right conditions for a successful community expansion includes the robustness, we believe of our market access efforts to date.

And I do think that those efforts and our operational support here, I think were part of the underlying reasons for despite the insurance resets and some of the COVID pandemic headwinds, we were still able to see a robust quarter-over-quarter growth in the first quarter of this year.

Okay, great. Thank you.

Thank you, Suji.

Hi, guys. Thanks for taking my questions and congrats on the first part of procurement this quarter.

Apologies for the issue with the phone earlier. First couple of questions is regarding NUZYRA.

Firstly, I think you had started engagement with the primary care physicians back in February. It's been roughly three months now and I know that you're expecting hopefully an expansion of the label later this month.

Maybe discuss for us a bit what you're hearing as you look to expand for the oral cap in the community, what you're hearing from physicians, the feedback that you're getting, and how you think that will tie into your expectations for the latter half of this year? And then more broadly, I was just wondering, certainly there's -- there's -- is early in the year given COVID, as well as the cycle of reimbursement.

But just wondering if you can give us a bit more detail of how you think the growth will sort of unfold for NUZYRA through the remainder of this year? Thanks.

Thanks, Ed, for those questions. Maybe Adam, you can talk a little bit about the inbound that we're hearing about the potential for the oral-only loading dose and how that will help with regards to your projected expansion success in the fall.

Yes. So, Ed, you asked also about how it's going in since February.

Look, we're really encouraged with what we're seeing. All signs are good and we're pleased with the uptake.

The feedback that we're getting on the skin side is very simple. Physicians are desperate for a really good once-a-day oral drug that has MRSA coverage.

And we're absolutely sure, based on what we're seeing that we'll continue to see uptake as we go through the bulk of the skin season, which is in the middle of this year. With regards to pneumonia, slightly different, we've conducted a number of advisory boards and we've done some market research.

Here, it's slightly different. What they're looking forward to with regard to NUZYRA is a drug that can be used in the elderly safely and with good monotherapeutic coverage of the relevant pathogens and a drug that doesn't cause [indiscernible].

Unfortunately, that's something that affects the older patient population quite a bit along with the QTc issue that you see with some of the drugs that are on the market. So, it's a safety story, as much as an efficacy story in community acquired pneumonia and in community acquired -- in skin, it's all about the efficacy because of the MRSA once-a-day drug.

So, we'll target those appropriate physicians along with their needs and based on the once-daily dosing, we're sure we're going to get good uptake. The only really efficacious therapies that are out there in oral form for pneumonia today are the quinolones and we know that they've got some significant limitations from a safety perspective and we'll take advantage of that.

Ed, in terms of your question with regards to how the growth might be expanding throughout the balance of the year, as you know, I think forecasting in the midst of the COVID pandemic really has provided real challenges for us for every company that's commercial at this point in time. But we continue to believe in the blockbuster potential of NUZYRA and I think the continued strong demand that we're seeing, as coupled to the start of prescriptions and adaption in the primary care setting, I think continues to fuel our continued belief in confidence in the future growth of NUZYRA.

We think that continued growth in the second half of this year, I think will be an exciting journey for all of us to be on and for us to be part of. I think there are many other components of contribution to that second half growth that includes a potential second BARDA procurement, I think, potential for DOD purchases as we've mentioned and continued organic growth in our overall institutional commitments, as well as what Adam has said, a further expansion in our primary care, estimated market addressable opportunities in the event that we get that FDA approval for our sNDA for the oral loading dose.

So we remain [indiscernible] and excited about all of that.

And Evan, I would add that we also anticipate a lifting of some of the restrictions that we see continuing the hospital and the move to the more impactful face-to-face interactions as we go through the year. And at behest [ph], we're already seeing.

Thank you for that, Adam. Thank you, Ed, for the questions.

As there are no more questions, we will conclude today's call. In closing, I'd like to thank you all for your time and attention today.

Your continued interest in NUZYRA and Paratek are important to us. The journey of making NUZYRA a commercial success is well underway.

As the wealth of microbiological data and clinical outcomes studies on NUZYRA continues to expand. We are increasingly confident in the potential of NUZYRA to be an effective and a much-needed addition to the armamentarium of antibiotics available to physicians to save lives, particularly where resistance is of concern.

The opportunities ahead of us to be able to provide a novel life-saving antibiotic to patients motivates us all here at Paratek. We would like to thank the patients who have participated in our clinical studies and our employees who have worked tirelessly and passionately to provide NUZYRA for patients in need and those selfless and dedicated healthcare professionals who are at the bedside each and every day.

We very much appreciate your continued support and interest. We look forward to keeping you apprised of our continued progress.

Goodbye for now.